Compare Quest Diagnostics Inc (DGX) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Eaton Corporation plc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Eaton Corporation plc trades at $429.65 (market cap $164.88B). The key difference: Eaton Corporation plc is far larger — about 6.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Eaton Corporation plc for 31 Days on average.
| DGX | ETN | |
|---|---|---|
Market Cap | $25.48B | $164.88B |
Volume | 941,866 | 2,535,086 |
Sector | Health | Industrials |
52-Week High | $247.45 | $459.96 |
52-Week Low | $173.49 | $315.82 |
Typical Hold Time | 56 Days | 31 Days |
Enterprise Value | $31.23B | $185.51B |
Dividend Yield | 1.49% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Eaton Corporation (ETN) trades at $429.65, down 0.39% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company maintains strong fundamentals with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, representing 17% upside potential from current levels.
ETN's outlook remains positive driven by data center demand and grid modernization trends, though elevated valuation multiples (P/E 43.23) and bearish technical signals warrant caution. The stock faces execution risks from recent acquisitions and competitive pressure in the electrical equipment sector, but strong institutional support and consistent earnings performance support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
